Results 141 to 150 of about 120,548,321 (260)

Neurologic uses of botulinum neurotoxin type A

, 2007
John P Ney, Kevin R JosephMadigan Army Medical Center, Neurology Service, Tacoma, WA, USAAbstract: This article reviews the current and most neurologic uses of botulinum neurotoxin type A (BoNT-A), beginning with relevant historical data, neurochemical ...
Kevin R Joseph, John P Ney
core  

The Impact of Outcome Measures for Responder Analyses in Placebo‐Controlled Trials of Pharmacological Treatments for Neuropathic Pain

European Journal of Pain, Volume 30, Issue 10, November 2026.
ABSTRACT Background Dichotomous responder outcomes, including ≥ 30% and ≥ 50% pain reduction, patient‐reported pain relief, and Patient Global Impression of Change (PGIC), are widely used in trials assessing interventions for neuropathic pain and have been suggested to be comparable, but their differences and influence on estimated treatment effects ...
Nanna Brix Finnerup, Sandra Sif Gylfadottir, Xavier Moisset, Andrea Truini, Ralf Baron, David L. Bennett, Margarita Calvo, Daniel Ciampi de Andrade, Patrick M. Dougherty, Elena K. Enax‐Krumova, Michael C. Ferraro, Ian Gilron, Aki Hietaharju, David Hohenschurz‐Schmidt, Koichi Hosomi, Harriet I. Kemp, Ewan McNicol, Jules Phalip, Theodore J. Price, Srinivasa N. Raja, Cristina Ramirez Piriz, Andrew S. C. Rice, Blair H. Smith, Nina Taule‐Lim, Jan Vollert, Jan D. Wandrey, Mohammad D. Zunaid, Nadine Attal, Simon Haroutounian   +28 more
wiley   +1 more source

Cosmetic use of botulinum toxin type A in the elderly

, 2007
Christine M ChengDepartment of Clinical Pharmacy, University of California, San Francisco, CA, USAAbstract: Botulinum toxin type A injections are one of the most popular cosmetic procedures for diminishing the appearance of facial lines caused by ...
Christine M Cheng
core  

Report of Adverse Events Associated With Cutaneous Procedures: Update From the CAPER Registry

Lasers in Surgery and Medicine, Volume 58, Issue 9, Page 796-801, November 2026.
ABSTRACT Objectives To systematically evaluate submissions to the CAPER database by analyzing procedural context, characteristics of reported adverse events (AEs), and provider involvement in order to identify patterns with potential implications for patient safety.
Sabrina S. Smith, Michael D. Yi, Elizabeth Zhang, Joycie Chang, Thanvi Gullapalli, Doroteja Dragovic, Vanessa J. Lazaro‐Camp, Ashish C. Bhatia, Arisa Ortiz, Murad Alam   +9 more
wiley   +1 more source

Botulinum Toxins Type A (Bont-A) in the Management of Lower Limb Spasticity in Children: A Systematic Literature Review and Bayesian Network Meta-analysis. [PDF]

J Child Neurol, 2019
Guyot P, Kalyvas C, Mamane C, Danchenko N.   +3 more
europepmc   +1 more source

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1479-1481, November 2026.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1500-1506, November 2026.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

The antigenic properties of Clostridium botulinum type E toxoids.

, 1958
The conditions responsible for the preparation of crude, activated and purified toxins of Clostridium botulinum Type E and the antigenic properties of toxoids prepared from these toxins, are described.
Strasdine, George Alfred
core   +1 more source

Urodynamic Voiding Patterns in Multiple Sclerosis

Neurourology and Urodynamics, Volume 45, Issue 8, Page 1569-1577, November 2026.
ABSTRACT Aims This study aimed to describe urodynamic voiding patterns in patients with MS (PwMS) using standardized assessments, and to compare the performance of the available nomograms and indices for obstruction and bladder contractility. Methods PwMS and lower urinary tract symptoms underwent cystometry and pressure flow studies.
Camille Chesnel, Nicolas Turmel, Maelys Teng, Emilie Blouet, Gérard Amarenco, Claire Hentzen   +5 more
wiley   +1 more source

Dose-dependent Effects of Botulinum Toxin Type E in the Mouse Digit Abduction Score Model. [PDF]

In Vivo
Ding Z, Jin C, Kim JY, Nam JS, Cha YK, Byeoun YG, Jeong JH, Na CM, Lee YH, Chien PN, Heo CY.   +10 more
europepmc   +1 more source